Most NSCLC patients harboring EGFR-activating mutations have a high response rate and achieve a survival benefit when treated with the first generation of EGFR-TKIs, gefitinib, or erlotinib4. This evidence concerns the gene EGFR and non-small cell lung carcinoma.